Integrase inhibitors
Dolutegravir; Lamivudine; Tenofovir Disoproxil Fumarate
The FDA lists this product in 3 strengths and forms.
Composition
- Active ingredients
- DOLUTEGRAVIR 50MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- DOLUTEGRAVIR 50MG; LAMIVUDINE 300MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TabletThis page
- DOLUTEGRAVIR 50MG/300MG/300MG; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE · TabletNDA210796-001 · Tentative approval
- DOLUTEGRAVIR 50MG/300MG/300MG; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE · TabletNDA211868-001 · Tentative approval
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA210787.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.